Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol measurement in Familial Dysbetalipoproteinemia

Clin Chim Acta. 2023 Jan 15:539:114-121. doi: 10.1016/j.cca.2022.11.035. Epub 2022 Dec 6.

Abstract

Aim: To compare LDL-C concentrations using the Friedewald formula, the Martin-Hopkins formula, a direct assay and polyacrylamide gradient gel electrophoresis (PGGE) to the reference standard density gradient ultracentrifugation in patients with Familial Dysbetalipoproteinemia (FD) patients. We also compared non-HDL-cholesterol concentrations by two methods.

Methods: For this study data from 28 patients with genetically confirmed FD from the placebo arm of the EVOLVE-FD trial were used. Four different methods for determining LDL-C were compared with ultracentrifugation. Non-HDL-C was measured with standard assays and compared to ultracentrifugation. Correlation coefficients and Bland-Altman plots were used to compare the methods.

Results: Mean age of the 28 FD patients was 62 ± 9 years, 43 % were female and 93 % had an ɛ2ɛ2 genotype. LDL-C determined by Friedewald (R2 = 0.62, p <0.01), Martin-Hopkins (R2 = 0.50, p = 0.01) and the direct assay (R2 = 0.41, p = 0.03) correlated with density gradient ultracentrifugation. However, Bland-Altman plots showed considerable over- or underestimation by the four methods compared to ultracentrifugation. Non-HDL-C showed good correlation and agreement.

Conclusion: In patients with FD, all four methods investigated over- or underestimated LDL-C concentrations compared with ultracentrifugation. In contrast, standard non-HDL-C assays performed well, emphasizing the use of non-HDL-C in patients with FD.

Keywords: Cholesterol; Density gradient ultracentrifugation; Direct homogeneous assay; FRIEDEWALD; Familial Dysbetalipoproteinemia; Low-density lipoprotein; Martin-Hopkins; Non-high-density lipoprotein; Polyacrylamide gels; Treatment goal; Type III hyperlipoproteinemia.

MeSH terms

  • Aged
  • Cholesterol
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Female
  • Humans
  • Hyperlipoproteinemia Type III* / drug therapy
  • Lipoproteins
  • Male
  • Middle Aged
  • Triglycerides

Substances

  • lipoprotein cholesterol
  • Cholesterol, LDL
  • Cholesterol
  • Lipoproteins
  • Triglycerides
  • Cholesterol, HDL